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STUDY PROTOCOL

Open Access

iKanEat: protocol for a randomized
controlled trial of megestrol as a
component of a pediatric tube weaning
protocol
Sarah Edwards1 , Paul E. Hyman2ˆ, Hayat Mousa3, Amanda Bruce4,5, Jose Cocjin1, Kelsey Dean4,5,
Kandace Fleming6, Rebecca Swinburne Romine6 and Ann M. Davis4,5*

Abstract
Background: Although tube feeding routinely saves the lives of children who do not eat by mouth, chronic tube
feeding can be a burden to patients, caregivers, and families. Very few randomized trials exist regarding the best
methods for weaning children from their feeding tubes.
Methods: The current paper describes a randomized controlled trial of an empirically supported outpatient
treatment protocol for moving children from tube to oral eating called iKanEat. Specifically, we describe the
methods of randomized double-blind, placebo-controlled trial which includes a 4-week course of megestrol, the
only medication used in the iKanEat protocol, to determine whether the addition of megestrol results in improved
child outcomes. The primary and secondary aims are to assess the safety and efficacy of megestrol as part of the
iKanEat protocol. The third aim is to provide critical information about the impact of the transition from tube to
oral feeding on parent stress and parent and child quality of life.
Discussion: This trial will provide data regarding whether megestrol is a safe and effective component of the
iKanEat tube weaning protocol, as well as important data on how the tube weaning process impacts parent stress
and parent and child quality of life.
Trial registration: ClinicalTrials.gov NCT#03815019. Registered on January 17, 2019
Keywords: Tube feeding, Tube weaning, Megestrol, Feeding problems, Randomized controlled trial

Background
Gastrostomy (G-) feeding tubes are placed in infants and
children who refuse to eat or have inadequate weight gain.
Common medical causes of inadequate weight gain
include neurological disease, congenital heart defects,
chronic pulmonary disease, renal failure, genetic disorders,
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anatomic abnormalities, behavioral disorders, and oropharyngeal dysphagia [1, 2]. Feeding tubes allow patients to
obtain sufficient nutrition [3]. Although the feeding tube
provides a way to ensure adequate nutrition, adverse outcomes can include infection of the G-tube insertion site,
granulation tissue, and leakage of gastric contents [4].
Some data indicate stress levels of caregivers can increase
after G-tube placement [5, 6]. Specifically, parents of tubefed children encounter multiple psychosocial stressors regarding tube feeding [7], which include concerns about
their child’s survival due to their underlying medical
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issues, feelings of “failure” due to their inability to
feed their child orally [8], increased feelings of stress
around the tube feeding [9], and decreased support
from others due to the tube feeding [10, 11]. It has
been demonstrated that initiating the transition from
tube to oral feeding as early as possible improves the
likelihood of successful tube weaning [3].
Existing treatment options for transitioning from tube
to oral feeding include outpatient, inpatient, and day
treatment. The most widely available treatment option is
outpatient treatment by a multidisciplinary team [12].
These teams include professionals from multiple specialties, including medical (pediatric gastroenterologist or
pediatrician), psychology, speech, occupational therapy,
and nutrition [13]. Outpatient treatment is typically covered by health insurance and can be tailored to meet the
needs of the patient and family. Typically, the patient
and family see the providers regularly (i.e., monthly,
quarterly) to receive recommendations that are then implemented in the home. This treatment option is effective for some patients, but other children require a more
intensive program for the tube weaning process.
Our team developed a novel interdisciplinary outpatient protocol for transitioning children from tube to
oral feeding [14, 15] called “iKanEat.” Previous data suggest iKanEat is effective for transitioning tube-fed children to eating by mouth [16] and results in statistically
significant and clinically meaningful increases in oral
eating. iKanEat was originally composed of several key
components, including two medications—amitriptyline
and megestrol. However, our most recent work (NIH
HD066629) [16] demonstrated that amitriptyline is not a
necessary component of the protocol, as all children
who completed the protocol consumed 100% of their
calories orally at post-treatment regardless of receiving
amitriptyline or placebo. Amitriptyline was subsequently
removed from the iKanEat protocol. The current protocol is a randomized controlled trial of the second medication (megestrol) compared to placebo, to assess
whether the addition of a 4-week course of megestrol
improves child outcomes within the iKanEat protocol.
Because corticosteroids can have significant side effects,
it is critical to determine if the benefits of megestrol as
part of iKanEat outweigh the risks of the medication. It
is imperative that we determine the efficacy and safety of
the protocol including 4 weeks of megestrol before we
move toward broad dissemination.
Megestrol is a steroid and progestational drug approved by the FDA for treating anorexia or weight
loss in adults with acquired immunodeficiency syndrome. The precise mechanism of action that leads to
increased appetite and weight gain is unknown, but is
likely related to megestrol’s glucocorticoid effect [10].
Side effects of megestrol may include suppression of
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the adrenal glands and new-onset diabetes mellitus
[10]. These complications are minimized by limiting
the duration of treatment to 6 weeks [10]. Other side
effects may include heart failure, nausea and vomiting,
edema, dyspnea, hyperglycemia, alopecia, hypertension, carpal tunnel syndrome, mood changes, malaise,
asthenia, lethargy, sweating, and rash [10].
Megestrol’s safety and efficacy have not been
established in children. However, there are several
pediatric trials with megestrol for anorexia or malnutrition [11, 17–20]. Two pediatric trials have
focused on megestrol to increase appetite in cancer
patients [17, 18]. Cuvelier and colleagues showed
clinically significant effects of megestrol on weight
gain (+ 19.7% versus placebo − 1.3%). Only two of
the 13 megestrol patients developed severe adrenal
insufficiency [17]. The other study employed megestrol as a second-line treatment if the child did not
respond to cyproheptadine (Periactin) [18]. Five of
the seven patients responded positively to megestrol,
and only one showed adrenal suppression [18]. A
retrospective study by Orme and colleagues again
demonstrated the effectiveness of megestrol in appetite, caloric intake, and weight gain, but the majority
of the patients exhibited some effects of adrenal suppression; one exhibited clinically significant adrenal
suppression [19]. These adrenal changes are reversible once the medication is discontinued, as demonstrated by a study with children with cystic fibrosis
[20]. In this randomized control trial of patients with
cystic fibrosis, patients in the treatment group
reached 100% of their ideal body weight within 3
months of initiating therapy and also improved their
pulmonary function [20]. While the majority showed
signs of adrenal suppression, it was reversible following cessation of treatment [20]. In a megestrol trial
for children with cystic fibrosis, the youngest child
treated was 6 months of age and treated with 10 mg
megestrol/day or placebo for 12 weeks [11].
The primary aim of the current study is to conduct a randomized double-blind, placebo-controlled
trial of a 4-week course of megestrol as a component of the iKanEat protocol. The primary aim is to
assess whether the addition of megestrol improves
child outcomes. The second aim is to assess the
safety of megestrol as part of the iKanEat protocol.
Our previous work (as well as work by others) suggests that a 6-week course of megestrol can lead to
adrenal insufficiency in some children [16–19], so as
part of the current protocol, we will assess the safety
of a 4-week course of this drug. Finally, the third
aim of the study is to examine the effect of the tube
to oral transition on parent stress and parent and
child quality of life.
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Methods
Specific aims and hypotheses
Aim 1

To assess the efficacy of megestrol as part of the 24week iKanEat protocol.
Hypothesis 1

Children randomized to the megestrol group will be
more successful in making the transition to oral feeding
(defined as obtaining at least 90% of calories orally) than
children randomized to the placebo group.
Aim 2

To assess the safety of 4 weeks of megestrol as part of
the 24-week iKanEat protocol.
Hypothesis 2A

Children randomized to the megestrol group will not
differ from control children in morning cortisol classification level (low, average, high) and will remain within
the normal range at all time points. Analyses 2B: Exploratory analysis will determine which, if any, covariates
(gender, age, diagnoses at week 0, and diagnoses at
birth) are related to abnormal morning cortisol levels.
Aim 3

To examine the effect of the transition from tube to oral
feeding on parent stress and parent and child quality of
life.
Hypothesis 3A

The transition to oral feeding will temporarily increase
parent stress at week 14 at the cessation of tube feeding;
for the children who successfully transition, we
hypothesize a return to baseline by week 24.
Hypothesis 3B

The successful transition to oral feeding will increase
parent/child quality of life at 24 weeks compared to
week 0.
Participant selection and withdrawal

Participants will be identified through multidisciplinary
feeding teams at 10 participating sites throughout the
USA. Parents of patients who meet the criteria will be
approached during feeding team visits or contacted by
feeding team staff. Methods of recruitment could include
approaching patients during routinely scheduled patient
visits, sending letters to patients identified through an
electronic medical record or other site-specific patient
registry, emailing patients through the electronic medical
record platform, or other recruitment methods as
allowed by the Institutional Review Board at each site.
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Seventy-two children (at least 60 completers) ages 0
year 9 months 0 day through 8 years 31 days will be recruited (see the “Sample size determination” section)
with a maximum of one child per family. To ensure an
equal balance of male and female across the two groups,
the statistical team will evaluate the percentage of male
in each group halfway through subject recruitment. If
there is not an equal proportion of male/female in each
group, the statisticians will implement a change in the
allocation tables of the randomization plan to correct
this. For inclusion/exclusion criteria, see Table 1, all of
which are consistent with the prior iKanEat study (NIH
HD066629). Children must receive over 80% of their
total daily calorie needs from a tube to be classified as
tube dependent. The lower age limit matches our recently completed feeding study. For the current study,
we set an upper limit of 8 years 31 days due to limitations of our measures which are only normed through
age 6 (meaning the child has to be 6 years or younger at
the final assessment point), and to improve the developmental homogeneity of our sample. However, during implementation, the upper age limit was increased to 9.0
years. The child must have a history of feeding problems
as identified by a diagnosis from a multidisciplinary
feeding team and must have permission from the physician on the team to ensure that they are medically
stable enough to participate in a weaning study. Finally,
they will be required to have oral motor skills sufficient
to promote positive oral eating, including oral skill development at or near the child’s developmental age (as
assessed by an Occupational Therapist or Speech
Language Pathologist at their site). The child will be excluded if they are receiving oral or inhaled steroids as
these can affect adrenal insufficiency. Families will be excluded if the parent has a known developmental delay or
cognitive impairment that may make participation in the
study difficult (children with these issues will not be excluded). Families will also be excluded if the child is
already currently receiving intensive (defined as more
than one session per month) behavioral feeding therapy
(previous feeding therapy is not an exclusion criterion).
Parents are required to be English speaking because
many of our measures are not validated in Spanish or
other languages. Children and families will continue all
ongoing medical care throughout the study.
A participant will be withdrawn from the study if more
than 0.5 kg of weight is lost consistently per week over
three consecutive weeks, or if 10% of total body weight
is lost. Children will also be removed if they have any
serious adverse event, such as significant negative
changes in mood, sleep, or food refusal. Children who
are removed from the study will be treated clinically.
If a participant drops from the study, they will be
asked to continue on with their assessments (at least
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Table 1 Inclusion/exclusion criteria
Inclusion criteria

Exclusion criteria

Child has a G or G/J tube

Parents have known significant developmental delay or cognitive impairment

Child receives > 80% kcal from the tube
Child ages 0 year 9 months 0 day through 8 years 31 days

Child is receiving intensive behavioral feeding therapy (> 1 session per month)
at the time of consent. Oral motor therapy is not an exclusion.

Physician permission to participate

Parents primary language other than English

Child has sufficient oral motor and behavioral skills for oral eating
(see Table 4)
Child has > 3-month history of feeding problem

Child receiving inhaled or oral steroids

Child has behavioral skills necessary for mealtime (see Table 4)

ClinicalTrials.gov (NCT#03815019) as outlined in
Table 2 procedure timeline. An outline of study activities
by year is presented in Table 3.

height and weight and diet recall, at the very minimum).
This will be done so we can have outcome on our primary endpoint even for subjects who drop out from
treatment. Unless a subject/parent actively refuses, we
will try to contact them for these assessments via phone
at least 5 times to schedule, and if this fails, we will attempt to reach them via certified letter at their last
known address.

Screening visit

Families who meet the criteria for participation (Table
1) will complete the consent process (with the site PI or
site research coordinator) and all baseline measures (see
the “Measures” section). Following consent and the completion of all baseline measures, the statistical team will
conduct blinded random assignment using computergenerated randomization codes and this information will
be communicated to the investigational pharmacy

Study procedures

All study procedures will be approved by the Institutional Review Board at the primary site (the University
of Kansas Medical Center) and are listed at
Table 2 Procedure timeline
Procedures

Pre
Week
(−14
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
to −
1
days)

Patient feeding/drug schedule
Tube feeding via G or G/J

X X X X X X X X X

Tube taper

X

X

Megestrol or placebo

X

X

X

X

Completed at each site
Eligibility

X

Informed consent

X

Demographics (REDCap)

X

Quality of life measures: PIP, ITQOL,
PQOL, PedsQL, CHQ (REDCap)

X

X

X

X

Clinic visit

X

X

X

X

Vitals (ht, wt, bp, temp, pulse)

X

X

X

X

X

X

X

X

X

X

X

Blood draw, morning cortisol
Subject payment ($100)

X

Dispense study drug

X

Completed by Kansas Team
3-day diet recall
Randomization
Tele-visit (30 min)

X

X
X
X

X

X

X

X

X

X

X

X

X

X

X
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Table 3 Timeline of study-related activities by year

only—all other staff will remain blind to group assignment throughout the study, making this a double-blind,
placebo-controlled trial.

skipped doses and report those to the study team at
their next visit.
Placebo

Megestrol

The proposed study will use megestrol 6 mg/kg/day in
two equal doses for 4 weeks [10, 11, 17]. Megestrol will be
dosed based on weight at the week 10 visit. The megestrol
will be dosed at full dose weeks 10–11, at 66% dose week
12, at 33% dose week 13, and fully tapered at the end of
week 13. The lead investigational pharmacy will coordinate with each site their purchase of the megestrol solution
from the single manufacturer. All sites will use the exact
formulation, containers, and dosing instructions as specified by the lead investigational pharmacy.
Participants will be given instructions on when to take
the medication and what to do if they miss a dose. If it
has been < 6 h since missing the dose, they should take
the dose as soon as they remember. If it has been ≥ 6 h
since missing the dose, they should skip the dose. Vomited doses should be re-dosed if within 30 min of original
dosing. Participants will be asked to document any

The investigational pharmacy developed a placebo that
is matched to the megestrol suspension in terms of taste,
appearance, viscosity, and storage properties. The placebo will have no active ingredients and will be provided
in the same containers, with the same labels and instructions for dosing as the active medication.
Randomization

Patients will be randomized within each site at a 1:1 ratio into the treatment and placebo groups. The statistical
team will generate ten sets of randomization codes and
send one set of codes to the pharmacist of each site. All
the other study personnel will be blinded to the result of
randomization.
The pharmacy at each site will prepare megestrol or
placebo for each subject as dictated by the random codes
prepared by the study statistician. The compound formula for each site will be identical, and the taste, look,
and smell of the placebo and megestrol will be matched.
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iKanEat intervention

Table 4 Definitions of oral motor, sensory, and behavioral skills

The 24-week iKanEat intervention is composed of 4
clinic visits and a series of 12 remote tele-visits (see
Table 2: procedure timeline). Serious adverse events
(SAEs) will be assessed at every point of contact. Clinic
visits will occur at each site in their clinical space. Each
visit will involve obtaining weight and height (in triplicate, in light clothing), vital signs, and then speaking
with a healthcare practitioner regarding overall health.
The child will also receive a complete physical exam,
similar to a routine pediatric visit, including blood pressure and temperature, and assessed for side effects of the
iKanEat protocol. Patients will also be sent to the lab for
procurement of blood serum to test for adrenal insufficiency at appropriate time points. At the initial clinic
visit, a medical history will also be obtained. Clinic visits
will occur at weeks 0, 10, 14, and 24. The megestrol will
be dosed at full dose weeks 10–11, at 66% dose week 12,
at 33% dose week 13, and fully tapered at the end of
week 13. Five days after the week 10 clinic visit, parents
will begin to taper G or G/J tube feedings by 10% each
day until they are stopped all together. The tube weaning schedule is outlined by the site PI, provided to the
family, and documented in the RedCap database.
Tele-visits (audio and video enabled) will begin by
building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding
habits, progress, stress of parent/child, and illness. Children will be assessed for side effects of the iKanEat
protocol at every tele-visit per parent report. Visits will
be scheduled around the child’s mealtime so that a feeding can be observed during the session. The majority of
the time left in the 30-min session will be spent dealing
with parent concerns, which our previous project indicates may include questions about measures, questions
about implementation of the iKanEat protocol, and
ensuring that children/families adhere to the oral motor
and behavioral guidelines for feeding (see Table 4).
Specifically, we will assess for the presence of daily mealtimes (at least 3–5 times per day), limited grazing
between planned meals/snacks, consistent mealtime location, appropriate meal length (approx. 20 min), and
limited distractions during mealtime (refrain from the
use of TV, iPad, toys, etc.). Families will also be encouraged to engage in family mealtime together, to prohibit
force feeding across all feeders, and to focus on positive
parent behavior, positive meal demeanor, and appropriate food presentation (as defined in Table 4). Motivational interviewing and cognitive-behavioral parent
training techniques will be used to improve parent
performance on these skill areas. These skills will rely
heavily on the detailed training manuals available from
The Incredible Years, and our therapists will specifically

Oral motor skills
Age-appropriate strength
and coordination of oral
cavity

Adequate range of motion, strength
and coordinated movement of the
lips, tongue, and jaw

Head/neck/trunk support

Strength and control of the head,
neck, and trunk to provide midline
stability of the body

Sensory issues
Sensory processing

Exposure to overcome sensory
processing issues that interfere with
daily life activities, specifically eating/
feeding

Behavioral skills
Regular meals

Coming to the meal setting at least 2–
3 times per day, willingly

Limited grazing

Child does not simply graze
throughout the day, but participates in
structured family mealtimes

Same location

Daily meals take place in the same
location

Meal length

Meal length falls between 10 and 20
min

Meal distractions

There are few distractions during
mealtime (i.e., TV) that occur on a
routine basis

Family mealtime

The child and family eat meals
together on a regular basis

Structured start and end

The parent dictates the start and end
of the meal with a simple command
such as “It’s time to eat” or “You may
get down now”

Parent behavior during
meals

Parent behavior during meals is
appropriate with limited coaxing and
no yelling or threatening

Force feeding

There is never any forcing of food or
other objects into the child’s mouth

Meal demeanor

Child is neutral or positive in response
to mealtime without crying or
constantly turning the head away
from the spoon

Good food presentation

Appropriate amount/variety of foods
are presented in a calm, relaxed
manner; feeders announce each bite

use the materials from the book Collaborating with Parents to Reduce Children’s Behavior Problems: A book for
Therapists Using the Incredible Years Programs. The
structure and content of these tele-visits is based directly
on those used in our prior work (NIH HD066629).
Tele-technology

Parents will be allowed to choose if they wish to receive
their tele-visits over phone (as we did in our previous
work) or via interactive televideo. For patients who
choose to do the visits over phone, we will provide a
toll-free number with a fully secure connection. For
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patients who choose to use the tele-visit option, we will
use the Zoom Mobile Meeting Platform which provides a
secure videoconference bridge. These point-to-point
connections are secure, meaning there is no concern
about the release of protected health information. The
Zoom platform also allows for the connection of diverse
types of systems, including mobile devices, desktop computers, and established telehealth equipment in many
clinical settings (important for eventual dissemination, if
appropriate). The Zoom m500 app or a similar secure
technology will be utilized to connect participants to the
study team for all procedures. No matter whether patients chose to receive their tele-visits over phone or
interactive televideo, they will be using their own existing device, such as a home phone, cell phone, desktop
computer, or tablet device.
Interventionists

Interventionists for the clinic visits will be pediatric gastroenterologists or pediatricians who specialize in feeding, accompanied by study team staff at each site. These
physicians are experts in feeding and serve as the physicians and/or Medical Directors of the feeding programs
at their sites. Interventionists for the tele-visits will be
behavioral experts at the primary site (KUMC) and are
trained multidisciplinary feeding team members with telehealth experience, including doctoral-level psychologists or their trainees. All behavioral interventionists are
trained in motivational interviewing and in cognitivebehavioral parent training and are familiar with The Incredible Years program that will serve as a basis for the
behavioral parent training program used here.
Fidelity

Treatment fidelity for tele-visits will be measured by
having a Graduate Research Assistant code a randomly
selected sample of 10% of all intervention sessions (via
recording). They will code for adherence to the visit
checklist, which will follow the procedure timeline. The
tapes will be selected and coded via a random numbers
table. Tapes are easily captured for tele-visits via digital
recording for phone and via existing technology for
interactive televideo apps.
Multi-site study

The current study is proposed at several sites in order to
recruit the number of children who meet the specific inclusion/exclusion criteria. Conducting a multi-site study
can present hurdles. However, many of the investigators
have worked together previously on feeding studies
(HD068221) and publications. To enhance protocol
adherence across sites, the PI will travel to each site annually, and the team will meet every year at the NASP
GHAN meeting. Also, a weekly mandatory 1-h phone
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conference will occur across all active sites to discuss
protocol implementation issues and patient safety. Sites
will be given written protocols during orientation that
define protocol deviations, unanticipated problems, and
adverse events, and the method to report those to the
lead site. Sites that have agreed to participate include the
University of Kansas Medical Center, Children’s Mercy
Hospital, University of California San Diego/Rady Children’s Hospital, Arnold Palmer Hospital for Children,
Children’s Hospital of Philadelphia, Vanderbilt University Medical Center, and Boston Children’s Hospital.
Additional sites available for recruitment, if the current
sites fall behind in their recruitment goals, include the
sites of our Data Safety Monitoring Board Members, and
sites that are members of the newly formed National
Feeding Consortium (of which the PI and several site PIs
are members). Sites will all have an existing multidisciplinary feeding team that includes at least a pediatric
healthcare provider (MD, DO, ARNP), Psychologist,
Dietitian, and Occupational Therapist/Speech Pathologist. The University of Kansas Medical Center will be
the lead and coordinating site. Research data will be entered by the sites into a REDCap data capture system
managed by the KUMC study team. Each individual site
PI and research coordinator will be responsible for recruitment at their site, as well as taking consent.
Measures

Data collection will occur as specified in Table 5. As in
our previous research, for two parent families, questionnaires will be completed by the primary parent associated with feedings.
All measures will be collected as outlined in Table 5.
Our primary outcome measure is percent kilocalories
obtained orally.
Percent kilocalories obtained orally

This measure will be obtained using the 24-h food recall
taken over 3 days. The 24-h food recall is a standardized
three-pass method, developed by the US Department of
Table 5 Measures timeline
Week
24-h food recall

0

10

14

24

X

X

X

X

X

X

Morning cortisol level
The Pediatric Inventory for Parents

X

X

X

X

Infant Toddler Quality of Life

X

X

X

X

Child Health Questionnaire Parent Form

X

X

X

X

Family Impact Module

X

X

X

X

Parent Quality of Life

X

X

X

X

Demographics

X
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Agriculture for use in national dietary surveillance. As
opposed to a food log or record (which is less scientifically rigorous), this recall is obtained over the phone by
trained dietitians using specific probes to gather significant details about items consumed. Although there are
weaknesses to every method of dietary assessment, this
one was selected as it is widely used in several large trials and data suggest it is the most valid and reliable
method of dietary assessment for children, and is considered the gold standard [21]. The data will be collected
using standardized probes by trained research staff, and
parents will be presented with paper food models and
measuring devices prior to interviews to reference during the recall. Recalls will be rigorously analyzed with
the Nutritional Data System for Research, version 2019;
University of Minnesota, Minneapolis, MN. Although a
plethora of information is available from this detailed,
scientific analysis, the current study will focus on total
daily oral calorie intake, and the percent of this intake
consumed orally.
Morning cortisol

The blood for the morning cortisol test will be drawn
before 8 am and run at the local site pediatric laboratory
to test for adrenal insufficiency. Because each laboratory
has its own reference range for morning cortisol depending upon the assay used, we will have labs report
both the actual value in units and the category description (low/within normal limits/high).
Parent stress (The Pediatric Inventory for Parents—PIP [22])

Parent stress will be measured via the Pediatric Inventory for Parents, a 52-item parent questionnaire developed to measure parent stress around caring for a
medically complicated child. The measure has a total
and four domain scale scores (communication, medical
care, role function, emotional function). For the purposes of the current study, we will assess the primary
caregiver (the parent who does the majority of the care
for the tube-fed child) and will use the total score, as
well as the four domain scale scores. The measure has
been shown to be a valid and reliable measure of
pediatric illness-related parenting stress [22].
Impact of pediatric chronic health conditions (PedsQL 2.0,
Family Impact Module)

The impact of pediatric chronic health conditions on
parents and the family will be measured with the
PedsQL 2.0, Family Impact Module (63) [23]. This 36item survey measures parent self-reported physical, emotional, social, and cognitive functioning; communication;
and worry. In addition, the Module assesses parentreported family daily activities and family relationships.
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Child quality of life (Infant Toddler Quality of Life—ITQOL
[24])

Child quality of life will be measured with the Infant
Toddler Quality of Life short-form questionnaire, validated for children 2 months through 5 years, 11 months,
31 days of age. The ITQOL has 47 items which result in
9 multi-item scales with well-established reliability
(Cronbach’s alpha > .70) and validity. Similar to our previous work [16], we will use the multi-item scales in our
analyses.
Parent quality of life (Parent Quality of Life SF-36v2)

Parent quality of life will be measured with the widely
used Parent Quality of Life Short Form 36, version 2.
Over 4000 studies have used the SF-36, making it a
widely accepted measure [25]. The 36 questions with 5point scales have 8 scaled scores: vitality, physical
functioning, bodily pain, general health perceptions,
physical role functioning, emotional role functioning, social role functioning, and mental health. As is typical, we
will convert individual scores to z-scores, resulting in a
standardized combined score [26]. This standardized
combined score will be used in analyses, as well as specific subscales that previous research indicates may be
sensitive to the current intervention (growth and development, behavior, general health perceptions, parental
impact: emotion, parental impact: time).
Child health-related quality of life (Child Health
Questionnaire Parent Form—CHQ-PF50)

Child quality of life in children ≥ 5 years old will be measured with the Child Health Questionnaire Parent Form
questionnaire. The parent-reported CHQ is normed for
ages 5 to 18 and measures 14 unique physical and psychosocial concepts. The CHQ has 50 items and scores
for the parent-reported versions can be analyzed at the
concept level (CHQ Profile Scores) or combined to derive an overall physical and psychosocial score (CHQ
Summary Scores).
Demographics

Families will complete a demographic questionnaire regarding age, race, ethnicity, income, insurance status,
and parental education, along with a medical history
questionnaire asking about diagnoses at birth and diagnoses at week 0 only. These variables will be used to describe our sample and in any covariate analyses.
Post-treatment questionnaire

Therapies outside of the iKanEat protocol will be
assessed via the post-treatment questionnaire at the final
clinic visit (week 24) and be available for use in analyses
as covariates if necessary.
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Safety

To monitor for any negative side effects, patients will be
contacted routinely (via the tele-visits and clinic visits
described previously) for any negative gastrointestinal,
behavioral, feeding, or other negative sequelae suspected
to result from our treatment. Any negative outcomes
identified will be reported to our Data Safety and Monitoring Board (DSMB; if required) and proper steps will
be taken. Under certain conditions (10% body weight
loss from the start of wean through any point later in
the protocol, and/or irritability or behavioral change unacceptable to parent or evaluator), children will be removed from the study and treated clinically. At every
clinic visit and tele-visit visit, we will record and evaluate
concomitant medications. Should any clinical concerns
be noted, appropriate medical/clinical treatments will
also occur as necessary. If any serious adverse events
occur, providers will be unblinded to the subject’s group,
the subject will be removed from the study, and patients
will receive all necessary treatment clinically.
Data Safety Monitoring Board

For the current study, we will have a Data Safety Monitoring Board that will review all subject safety data twice
annually after the first 5 subjects are enrolled through
the end of the study. Twice a year, the DSMB will review
protocol adherence, adverse events, unanticipated problems, voluntary and study team initiated withdrawals,
etc. This team is also available to the investigators at any
time should an issue of safety arise. Any serious adverse
events will be reported immediately to the relevant institutional IRBs and to the DSMB.
Unresolved adverse events

All unresolved adverse events should be followed by the
investigator until the events are resolved, the subject is lost
to follow-up, or the adverse event is otherwise explained.
At the last scheduled visit, the investigator should instruct
each subject to report any subsequent event(s) that the
subject, or the subject’s personal physician, believes might
reasonably be related to participation in this study. The investigator should notify the study sponsor of any death or
adverse event occurring at any time after a subject has discontinued or terminated study participation that may reasonably be related to this study. The sponsor should also
be notified if the investigator should become aware of the
development of cancer or of a congenital anomaly in a
subsequently conceived offspring of a subject that has participated in this study.
Analysis plan
Sample size determination

Sample size determination was calculated using Power
Analysis & Sample Size (PASS) software. If at least 90%
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of the treatment group successfully transitions (in pilot
100% successfully transitioned [16]), with 72 participants, we would have .80 power to detect an odds ratio
of .21. With 60 participants, we would have power to detect an odds ratio of .18.

Planned analyses

Analyses will be conducted using Generalized Linear
Mixed Models with a logit link within SAS Proc GLIM
MIX to model the binary outcome of transitioned to oral
feeding (y/n) defined as at least 90% of calories
consumed orally. Fixed effects (dummy variables) will
be entered for each site as described by McNeish and
Stapleton to account for the clustering of the participants within sites [27]. This will result in a logistic
regression model with appropriate standard errors.
Sex, age at initiation, treatment condition, and interactions with treatment condition will be included in
the models to enable us to examine the effect of
group assignment on successful transition to oral
feeding by week 24. Interactions between the treatment group and sex will be examined but will not be
sufficiently powered to reach definitive conclusions
about sex differences. In addition to overall effects,
subgroup analyses will be reported for males and females to examine treatment effects within sex groups.
Should any participant have cortisol levels outside of
the normal range, we will examine the individual
characteristics associated with this, including group assignment, medical diagnoses, sex, and age at initiation.
These characteristics will be reported descriptively.
We will model parent stress levels, child quality of life,
and parent quality of life for participants in both treatment conditions over the four measurement occasions
using General Linear Mixed Models. As in aim 1, fixed
effects for the site will be added to the model as will sex
and age at initiation. Once the shape of the trajectory
over time has been modeled, a successful transition to
oral feeding indicator, defined as consuming 90% or
more of calories orally, will be added to the model at
level 2. For 3A, the primary interest will be the time by
successful transition interaction on parental stress level.
Estimate statements will examine group differences in
stress at weeks 14 and 24. To address hypothesis 3B regarding quality of life outcomes, we will initially model
the trajectory over time for each outcome with the same
set of predictors as in 3A.

Population(s) for analysis

Our primary analysis will focus on a protocol-compliant
population, but we will secondarily also analyze the alltreated population, as described below.
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 All-randomized population: Any subject randomized

into the study, regardless of whether they received
study drug
 All-treated population: Any subject randomized into
the study that received at least one dose of study
drug
 Protocol-compliant population: Any subject who
was randomized and received the protocol required
study drug exposure and required protocol
processing
Data handling

Data will be collected using REDCap, which allows the
ability to ensure responses have complete data. Study
coordinators will verify the data during the clinic visit to
ensure data collection was accurate and complete.
Site PI and site study coordinators will have access to
their own site’s data. The lead PI and study team will
have access to data from all sites. Sites will not have access to other site’s identified data. De-identified aggregate data may be shared for safety monitoring during
site conference calls and to the DSMB. The lead Investigational Pharmacy will have access to identified data
from each site for drug randomization.
Data will be shared from the sites to the coordinating
site via REDCap or secure file transfer. Data will be
saved onto secured shared drives at KUMC and on
shared drives at the site’s home institutions. KUMC will
retain the data for 10 years after the completion of the
study or once subjects turn 18 years old.
Identifiable information will be collected. Information
will be coded with a subject ID and identifiers will be removed to a linking list that will be saved in a separate location. The lead PI and study coordinator will have
access to all coded data. Site PI and coordinators will
have access to the linking log for their site only. Identified data will be located in REDCap. Once data are abstracted from REDCap, they will be saved on the KUMC
shared drives where identifiers will be removed and
placed into a linking log. Identifiable data will be sent
from the site to KUMC using secure file transfer.
Data will be stored in REDCap and on the lead site secure shared drives. Consent will be obtained electronically via REDCap. REDCap may be brought up on a
mobile device for participants to complete; however, no
data will be stored directly on the mobile device.
Confidentiality

Information about study subjects will be kept confidential and managed according to the requirements of the
Health Insurance Portability and Accountability Act of
1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:
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 What protected health information (PHI) will be

collected from subjects in this study
 Who will have access to that information and why
 Who will use or disclose that information
 The rights of a research subject to revoke their

authorization for use of their PHI
In the event that a subject revokes authorization to
collect or use PHI, the investigator, by regulation, retains
the ability to use all information collected prior to the
revocation of subject authorization. For subjects that
have revoked authorization to collect or use PHI, attempts will be made to obtain permission to collect at
least vital status (i.e., that the subject is alive) at the end
of their scheduled study period.
Ethics and dissemination

This study will be conducted according to US and international standards of Good Clinical Practice (FDA Title
21 part 312 and International Conference on
Harmonization guidelines), applicable government regulations, and Institutional research policies and procedures. This protocol has been approved by the
University of Kansas Medical Center’s Institutional Review Board (KUMC IRB), which is serving as the central
IRB (through the SMART IRB system). Any protocol
modifications are submitted to the KUMC IRB for approval and communicated to each of the participating
sites. All subjects for this study will be provided a consent form describing this study and providing sufficient
information for subjects to make an informed decision
about their participation in this study. The formal consent of a subject, using the EC/IRB-approved consent
form, must be obtained before that subject undergoes
any study procedure. The consent form must be signed
by the subject or legally acceptable surrogate, and the
investigator-designated research professional obtaining
the consent. The findings of the study will be presented
at national conferences and published in peer-reviewed
journals. The study sponsor and funder has no role in
the collection, management, analysis, interpretation, or
writing of the report. Professional writers will not be
used in the composition of the manuscript.

Discussion
Existing treatment options for children with feeding
problems transitioning from tube to oral feeding are
limited. Previous studies of our outpatient protocol
(iKanEat) have demonstrated promising results, but the
randomized controlled trial described herein is a critical
next step in the assessment of the necessity of megestrol
as a component of this treatment program. The results
regarding the safety of megestrol will also likely be
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helpful to physicians and families considering the use of
megestrol for other clinical populations, such as children
with cystic fibrosis or those with cancer.

USA. 4Department of Pediatrics, University of Kansas Medical Center, 3901
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